StemCyte International (TPE:4178) Other Current Payables: NT$37.5 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4178 StemCyte International Ltd TPE:4178
7 GF Score
Price NT$18.40
! 4 Warning Signs
View Full Analysis

What is StemCyte International Other Current Payables?

StemCyte International TPE:4178 -2.39% 7 Other Current Payables is NT$37.5 Mil as of Mar. 2026. GuruFocus rates TPE:4178 with a GF Score™ of 7/100. The stock has 4 warning signs investors should review.

StemCyte International's Other Current Payables for the quarter that ended in Mar. 2026 was NT$37.5 Mil.

StemCyte International's quarterly Other Current Payables increased from Sep. 2025 (NT$35.9 Mil) to Dec. 2025 (NT$48.6 Mil) but then declined from Dec. 2025 (NT$48.6 Mil) to Mar. 2026 (NT$37.5 Mil).

StemCyte International's annual Other Current Payables increased from Dec. 2023 (NT$42.9 Mil) to Dec. 2024 (NT$45.4 Mil) and increased from Dec. 2024 (NT$45.4 Mil) to Dec. 2025 (NT$48.6 Mil).

StemCyte International Other Current Payables Related Terms

StemCyte International Other Current Payables Historical Data

* Premium members only.

The historical data trend for StemCyte International's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StemCyte International Other Current Payables Chart

StemCyte International Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Other Current Payables
34.84 42.94 45.44 48.60

StemCyte International Quarterly Data
Dec22 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 32.26 35.95 48.60 37.54
TPE:4178
7GF Score
StemCyte International Ltd TPE:4178
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StemCyte International Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of NT$37.5 Mil mean?
StemCyte International (TPE:4178) has a Other Current Payables of NT$37.5 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on StemCyte International and its competitors.
Is StemCyte International's Other Current Payables too high?
StemCyte International's current Other Current Payables is NT$37.5 Mil. Overall, StemCyte International has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does StemCyte International's Other Current Payables compare to VRTX and REGN?
StemCyte International's Other Current Payables of NT$37.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on StemCyte International and its competitors. StemCyte International's current Other Current Payables is NT$37.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCyte International stock overvalued right now?
StemCyte International (TPE:4178) has a current Other Current Payables of NT$37.5 Mil. The current Other Current Payables is NT$37.5 Mil. StemCyte International's overall GF Score™ is 7/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For StemCyte International (TPE:4178), the current Other Current Payables is NT$37.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

StemCyte International Business Description

Address Zhongxiao East Raod, 9th Floor-2, No. 508, Section 7, Nangang District, Taipei, TWN
StemCyte International Ltd is engaged in developing new stem cell drugs and test, process, and store umbilical cord blood (UCB)-related cells. The company's main operating activities are providing umbilical cord blood collection, processing and storage services. Its reportable segments are the United States, Taiwan, and Others. The majority of revenue is derived from the United States.
7GF Score

Get the complete analysis for TPE:4178

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$18.40
Price